Avexa Limited – Manufacture of ATC product for Named Patient Scheme completed Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 9th September 2014   Melbourne, Australia, Tuesday 9th September 2014: Australian biotechnology company Avexa Limited [ASX:AVX] today announced that the manufacture of ATC product intended for its Early Access / Named Patient Scheme has been completed successfully, on schedule and is

LINK Healthcare receives marketing approval for DermaScar®  DermaScar® (polysiloxane) is a scar reduction gel for the treatment of keloid and hypertrophic scarring.  Link’s newly formed Pharmacy Division expects more specialist products to follow Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 1st September 2014   Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) announced today that it has